2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 626

The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
Abstract Number: 2877

The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Abstract Number: 615

The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis
Abstract Number: L15

The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
Abstract Number: 864

The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis
Abstract Number: 2089

The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
Abstract Number: 1626

The Disease Expression in Familial and Sporadic Axial Spondyloarthritis Patients
Abstract Number: 1182

The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases
Abstract Number: 1016

The Distinct Profile of Ly6clo Monocytes in the Murine Joint Compared with Those in Circulation Suggests a Unique Role in Inflammatory Arthritis
Abstract Number: 1183

The Distribution of Insurance in a Population-Based Cohort of SLE: Georgians Organized Against Lupus Cohort, 2012-2016
Abstract Number: 1180

The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Commercially-Insured Population in the United States Stratified By Disease Severity
Abstract Number: 2996

The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Medicaid Cohort Stratified By Disease Severity
Abstract Number: 1951

The Effect and Psychosocial Impact of a Longstanding Telephone Peer Counseling Service on Volunteers with Systemic Lupus Erythematosus
Abstract Number: 1992

The Effect of 4E-BP1 on Osteoarthritis-Related Gene Expression in TGF-β1-Stimulated Chondrocytes
Abstract Number: 2734

The Effect of Age at Diagnosis on Mortality in ANCA-Associated Vasculitides

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].